Article
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Lung cancer (Amsterdam, Netherlands) - 1 Sept 2015
Klempner Samuel J, Bazhenova Lyudmila A, Braiteh Fadi S, Nikolinakos Petros G, Gowen Kyle, Cervantes Claudia M, Chmielecki Juliann, Greenbowe Joel R, Ross Jeffrey S, Stephens Philip J, Miller Vincent A, Ali Siraj M, Ou Sai-Hong Ignatius
Abstract excerpt
OBJECTIVES: The gatekeeper mutation T790M mutation is the responsible for the majority of the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Other previously described resistance mechanisms include HER2 amplification, MET amplification, PIK3CA mutation, epithelial-mesenchymal transition (EMT), small cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.